Compare Cytokinetics Inc (CYTK) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Hut 8 Corp — how do they compare? Cytokinetics Inc trades at $61.8 (market cap $8.62B), while Hut 8 Corp trades at $79.33 (market cap $9.82B). The key difference: Cytokinetics Inc and Hut 8 Corp are close in size by market cap, and Hut 8 Corp is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Hut 8 Corp for 11 Days on average.
| CYTK | HUT | |
|---|---|---|
Market Cap | $8.62B | $9.82B |
Volume | 2,594,626 | 10,272,678 |
Sector | Health | Financials |
52-Week High | $87.26 | $133.02 |
52-Week Low | $54.76 | $33.76 |
Typical Hold Time | 19 Days | 11 Days |
Enterprise Value | $8.72B | $17.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
HUT trades at $89.3, down 3.17% today, amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 with a negative net margin, though revenue grew to $235.12 million. Recent news highlights a $1.07 billion credit facility and AI infrastructure deals, fueling optimism. Analyst consensus is strongly bullish with a $156.79 price target.
The outlook balances strong analyst support and AI infrastructure growth potential against persistent losses and high valuation multiples. Key risks include execution on profitability and competitive pressures in the digital infrastructure space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
